Sunshine Biopharma (NASDAQ:SBFM) Announces Quarterly Earnings Results, Misses Expectations By $9.94 EPS

Sunshine Biopharma (NASDAQ:SBFM) announced its quarterly earnings results on Tuesday. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of $9.00 by ($9.94), Zacks reports. Sunshine Biopharma had a negative net margin of 12.07% and a negative return on equity of 16.09%. The business had revenue of $8.44 million for the quarter.

Sunshine Biopharma Price Performance

SBFM opened at $2.68 on Thursday. The company’s 50-day moving average is $2.96 and its 200 day moving average is $1.65. The firm has a market capitalization of $3.27 million, a PE ratio of -0.01 and a beta of 1.38. Sunshine Biopharma has a fifty-two week low of $2.42 and a fifty-two week high of $637.20.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.